RGPX
REGENEREX PHARMA, INC.
Key Financials
Gross Profit
$-244917
↓ 27434.5%
Revenue
$1775
↓ 31.9%
Total Liabilities
$5.4M
↑ 12.2%
Operating Income
$-1826097
↑ 47.3%
Shareholders' Equity
$-4156205.00
↓ 2.3%
Total Assets
$1.3M
↑ 64.8%
Cash & Equivalents
$653025.00
↑ 175444.4%
Net Income
$-2527041
↑ 28.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/22/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| 8-K | 4/2/2026 | View on SEC |
| NT 10-K | 3/30/2026 | View on SEC |
| 10-Q | 11/17/2025 | View on SEC |
| NT 10-Q | 11/17/2025 | View on SEC |
| 8-K | 11/12/2025 | View on SEC |
| 8-K | 9/3/2025 | View on SEC |
| 10-Q | 8/14/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RGPX |
| Company Name | REGENEREX PHARMA, INC. |
| CIK | 1357878 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 305-927-5191 |